These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 2407093)

  • 41. Antiarrhythmic drug therapy for suppression of ventricular arrhythmia: experience with 122 patients treated for two years.
    Salerno DM; Fifield J; Hodges M
    J Clin Pharmacol; 1990 Mar; 30(3):226-34. PubMed ID: 2312780
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical pharmacokinetics of moricizine.
    Siddoway LA; Schwartz SL; Barbey JT; Woosley RL
    Am J Cardiol; 1990 Feb; 65(8):21D-25D; discussion 68D-71D. PubMed ID: 2407090
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiarrhythmic agents for chronic ventricular arrhythmias.
    Nestico PF; Morganroth J
    Compr Ther; 1987 Apr; 13(4):26-35. PubMed ID: 3105950
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [A preliminary report on the antiarrhythmic effect of ethmozine].
    Fang WH
    Zhonghua Xin Xue Guan Bing Za Zhi; 1988 Jun; 16(3):154-5. PubMed ID: 3065022
    [No Abstract]   [Full Text] [Related]  

  • 45. The changing base line of complex ventricular arrhythmias. A new consideration in assessing long-term antiarrhythmic drug therapy.
    Pratt CM; Delclos G; Wierman AM; Mahler SA; Seals AA; Leon CA; Young JB; Quinones MA; Roberts R
    N Engl J Med; 1985 Dec; 313(23):1444-9. PubMed ID: 3903506
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antiarrhythmic drug therapy (Part 2). Benefits and hazards.
    Podrid PJ
    Chest; 1985 Oct; 88(4):618-24. PubMed ID: 3930162
    [No Abstract]   [Full Text] [Related]  

  • 47. A benefit-risk assessment of class III antiarrhythmic agents.
    Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L
    Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST).
    Peters RW; Mitchell LB; Brooks MM; Echt DS; Barker AH; Capone R; Liebson PR; Greene HL
    J Am Coll Cardiol; 1994 Feb; 23(2):283-9. PubMed ID: 8294678
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Comparative study of the effectiveness of ethacizine, etmozin and Ritmilen in patients with ventricular rhythmic disorders].
    Smetnev AS; Ponomarenko EL; Koltunova MI; Shugushev KhKh
    Kardiologiia; 1987 May; 27(5):24-6. PubMed ID: 2443743
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Can antiarrhythmic drugs survive survival trials?
    Pratt CM; Waldo AL; Camm AJ
    Am J Cardiol; 1998 Mar; 81(6A):24D-34D. PubMed ID: 9537220
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and efficacy of a twice-daily dosing regimen for moricizine (ethmozine).
    Morganroth J
    Am Heart J; 1985 Dec; 110(6):1188-92. PubMed ID: 3907314
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Overview: moricizine--can it meet the challenge?
    Morganroth J; Bigger JT
    Am J Cardiol; 1990 Feb; 65(8):1D-2D; discussion 68D-71D. PubMed ID: 2407086
    [No Abstract]   [Full Text] [Related]  

  • 53. Moricizine-induced proarrhythmia.
    Seaborg SM; Cowan MD
    Clin Cardiol; 1992 Nov; 15(11):866-7. PubMed ID: 10969633
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New antiarrhythmic drugs: their place in therapy.
    Keefe DL; Kates RE; Harrison DC
    Drugs; 1981 Nov; 22(5):363-400. PubMed ID: 6800757
    [No Abstract]   [Full Text] [Related]  

  • 55. [New aspects of the clinical use of anti-arrhythmia agents with special reference to acute therapy of ventricular tachycardia (lidocaine vs. ajmaline)].
    Manz M; Mletzko R; Jung W; Lüderitz B
    Herz; 1990 Apr; 15(2):79-89. PubMed ID: 2188894
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiarrhythmic drug therapy. Recent advances and current status.
    Somberg J
    Cardiology; 1985; 72(5-6):329-48. PubMed ID: 2866841
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ethmozine suppression of single and repetitive ventricular premature depolarizations during therapy: documentation of efficacy and long-term safety.
    Pratt CM; Yepsen SC; Taylor AA; Mason DT; Miller RR; Quinones MA; Lewis RA
    Am Heart J; 1983 Jul; 106(1 Pt 1):85-91. PubMed ID: 6346845
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ethacizin: a new efficacious Soviet antiarrhythmic drug of the phenothiazine group.
    Rosenshtraukh LV; Shugushev KK; Smetnev AS
    Am Heart J; 1986 Nov; 112(5):932-9. PubMed ID: 3535466
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selection of an antiarrhythmic drug for a sudden-death-prevention trial.
    Woosley RL; Roden DM; Duff HJ; Oates JA
    Am Heart J; 1982 Apr; 103(4 Pt 2):737-45. PubMed ID: 6175198
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical pharmacology of antiarrhythmic agents.
    Kelliher GJ; Kowey P; Engel T; Wetstein L
    Cardiovasc Clin; 1985; 16(1):287-305. PubMed ID: 2874883
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.